Research programme: antibody therapuetics - Treadwell Therapeutics
Latest Information Update: 19 Apr 2022
At a glance
- Originator University Health Network
- Developer Treadwell Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer